Información del artículo
Resumen
En la Digestive Disease Week 2012 se han presentado numerosos trabajos sobre el tratamiento, la monitorización y la seguridad de los fármacos en la enfermedad inflamatoria intestinal. Se han evaluado nuevas indicaciones de los tratamientos previamente aprobados, principalmente en la enfermedad perianal y en la prevención de la recurrencia posquirúrgica. Además se han aportado nuevos datos sobre marcadores biológicos que podrían ayudarnos en el seguimiento de los pacientes con enfermedad inflamatoria intestinal. Se han presentado diversos estudios sobre la seguridad de los fármacos tiopurínicos y anti-TNF durante el embarazo. Pero, sin duda, gran parte de la atención se ha centrado en los estudios que determinan los valores de fármacos anti-TNF y anticuerpos contra dichos fármacos, evaluando nuevas técnicas con mayor exactitud diagnóstica, su correlación con la respuesta clínica y su utilidad en la optimización del tratamiento de los pacientes con enfermedad inflamatoria intestinal.
Palabras clave:
Enfermedad inflamatoria intestinal
Colitis ulcerosa
Enfermedad de Crohn
Azatioprina
Infliximab
Adalimumab
Abstract
In Digestive Disease Week 2012, numerous studies were presented on the treatment, monitoring and safety of drugs in inflammatory bowel diseases. New indications for previously approved treatments were evaluated, mainly in perianal disease and the prevention of postsurgical recurrence. New data were provided on biological markers that could help in the follow-up of patients with inflammatory bowel disease. Several studies were presented on the safety of thiopurine drugs and anti-tumor necrosis factor (TNF) agents during pregnancy. However, much of the meeting was centered on studies determining levels of anti-TNF agents and antibodies against them, evaluating new techniques with greater accuracy in determining levels of these agents and antibodies against them, their correlation with clinical response and their utility in optimizing the treatment of patients with inflammatory bowel disease.
Keywords:
Inflammatory bowel disease
Ulcerative colitis
Crohn's disease
Azathioprine
Infliximab
Adalimumab
El Texto completo está disponible en PDF
Bibliografía
[1.]
D.J. Stobaugh, P. Deepak, B. Hannon, E.D. Ehrenpreis.
Predicting regional colonic concentrations of 5-aminosalicylic acid (5- ASA) from oral and topical therapy with dynamic modeling in ulcerative colitis.
Gastroenterology, 142 (2012), pp. S389
[2.]
W.J. Sandborn, S. Danese, E. Ballard, L. Moro, R.J. Jones, R. Bagin, et al.
Efficacy of budesonide MMx(r) 6mg QD for the Maintenance of remission in patients with ulcerative colitis: results from a phase III, 12 month safety and extended use Study.
Gastroenterology, 142 (2012), pp. S564
[3.]
S. Travis, S. Danese, E. Ballard, L. Moro, R.J. Jones, R. Bagin, et al.
Safety analysis of budesonide MMx 6mg used for the maintenance of remission in patients with ulcerative colitis: results from a phase III, 12 month safety and extended use study.
Gastroenterology, 142 (2012), pp. S566-S567
[4.]
G.R. Lichtenstein, S. Danese, E. Ballard, L. Moro, R.J. Jones, R. Bagin, et al.
Effect of budesonide MMx 6mg on the hypothalamicpituitary- adrenal (HPA) axis in patients with ulcerative colitis: results from a phase III, 12 month safety and extended use study.
Gastroenterology, 142 (2012), pp. S785
[5.]
D. Laharie, A. Bourreille, J. Branche, M. Allez, Y. Bouhnik, J. Filippi, et al.
Cyclosporin versus infliximab in severe acute ulcerative colitis refractory to intravenous steroids: a randomized trial.
Lancet. En prensa, (2011),
[6.]
M. Protic, A. Schoepfer, P. Frei, P. Juillerat, C. Mottet, J. Mwinyi, et al.
Comparative short-term response and remission rates for tacrolimus, cyclosporine and infliximab for steroid-refractory ulcerative colitis.
Gastroenterology, 142 (2012), pp. S358
[7.]
H. Aoki, R. Furukawa, Y. Suzuki.
Oral tacrolimus versus cyclosporine a in patients with moderate to severe ulcerative colitis refractory to corticosteroids.
Gastroenterology, 142 (2012), pp. S205
[8.]
T. Fujii, M. Naganuma, E. Saito, M. Nagahori, M. Watanabe.
Intravenous tacrolimus therapy can rapidly induce remission in refractory ulcerative colitis.
Gastroenterology, 142 (2012), pp. S356
[9.]
S. Hiraoka, J. Kato, H. Suzuki, T. Hirakawa, M. Akita, S. Saito, et al.
Readministration of calcineurin inhibitors is not effective for ulcerative colitis patients who relapsed after remission by treatment with calcineurin inhibitors.
Gastroenterology, 142 (2012), pp. S799
[10.]
A. Armuzzi, L. Biancone, M. Daperno, A. Coli, V. Annese, S. Ardizzone, et al.
Adalimumab in active ulcerative colitis: a real-life observational study.
Gastroenterology, (2012), pp. 142
[11.]
J. Markowitz, K. Grancher, N. Kohn, M. Lesser, F. Daum.
A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease.
Gastroenterology, 119 (2000), pp. 895-902
[12.]
M. Sans, A. López-San Román, M. Esteve, F. Bermejo, V. García-Sánchez, Y. Torres, et al.
Early Use of azathioprine has a steroid sparing effect on recently diagnosed Crohn's disease patients.
Gastroenterology, 140 (2011), pp. S109
[13.]
J. Cosnes, A. Bourrier, D. Laharie, Y. Bouhnik, S. Nahon, J. Bonnet, et al.
Accelerated step-care therapy with early azathioprine (AZA) vs. conventional step-care therapy in Crohn's disease: a randomized study.
Gastroenterology, (2012), pp. 142
[14.]
G. Van Assche, C. Magdelaine-Beuzelin, G. D’Haens, F. Baert, M. Noman, S. Vermeire, et al.
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.
Gastroenterology, 134 (2008), pp. 1861-1868
[15.]
H. Sokol, P. Seksik, F. Carrat, I. Nion-Larmurier, A. Vienne, L. Beaugerie, et al.
Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
Gut, 59 (2010), pp. 1363-1368
[16.]
C. Reenaers, E. Louis, J. Belaiche, S. Keshav, S. Travis.
Immunosuppressive co-treatment with adalimumab (ADA) may be more effective than ada monotherapy for maintaining remission in Crohn's disease (CD).
Gastroenterology, 142 (2012), pp. S352
[17.]
A.C. Stein, D.T. Rubin, S.B. Hanauer, R.D. Cohen.
Predictors of clinical response, re-induction dose, and dose increase with cetolizumab pegol in Crohn's disease.
Gastroenterology, 142 (2012), pp. S355-S356
[18.]
W.J. Sandborn, B.G. Feagan, R.N. Fedorak, E. Scherl, M.R. Fleisher, S. Katz, et al.
A randomized trial of ustekinumab, a human interleukin- 12/23 monoclonal antibody, in patients with moderate- to-severe Crohn's disease.
Gastroenterology, 135 (2008), pp. 1130-1141
[19.]
W.J. Sandborn, C. Gasink, L.L. Gao, M. Blank, J. Johanns, C. Guzzo, et al.
A Multicenter, randomized, double-blind, placebo-controlled phase2b study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately to severely active Crohn's disease: results through week 22 from the Certifi Trial.
Gastroenterology, 140 (2011), pp. S109
[20.]
D. Ginard, S. Khorrami, I. Marín-Jiménez, M. Chaparro, M. Aguas, F. Muñoz, et al.
Effectiveness and safety of ustekinumab as rescue therapy in multi-drug resistant Crohn's disease.
Gastroenterology, 142 (2012), pp. S355
[21.]
G. Rosenfeld, H. Qian, B. Bressler.
Post-operative complications following pre-operative infliximab use in Crohn's disease patients undergoing abdominal surgery: a meta-analysis.
Gastroenterology, 142 (2012), pp. S248
[22.]
U. Kopylov, S. Ben-Horin, O. Zmora, A.R. Eliakim, L.H. Katz.
Anti- TNFs and post-operative complications in Crohn's disease: systematic review and meta-analysis.
Gastroenterology, 142 (2012), pp. S250
[23.]
I. Arijs, J. Van der Goten, G. De Hertogh, M. Ferrante, K. Machiels, L. Van Lommel, et al.
Mucosal gene expression differences between early and post-operative recurrent/late ileal Crohn's disease suggest increased inflammatory load in early disease.
Gastroenterology, 142 (2012), pp. S881
[24.]
A. Armuzzi, C. Felice, M. Marzo, D. Pugliese, G. Andrisani, A. Papa, et al.
Prevention of postoperative recurrence with azathioprine or anti-TNF alpha in patients with Crohn's disease: an openlabel pilot study.
Gastroenterology, 142 (2012), pp. S780
[25.]
M. Aguas, G. Bastida, E. Cerrillo, B. Beltrán, M. Iborra, F. Muñoz, et al.
Impact of adalimumab in the prevention of postoperative recurrences of Crohn's disease in high-risk patients.
Gastroenterology, 142 (2012), pp. S384
[26.]
C. Castano-Milla, M. Chaparro, C. Saro, M. Barreiro-de Acosta, A.M. García-Albert, L. Bujanda, et al.
Effectiveness of adalimumab in the treatment of perianal fistulas in patients with Cronh's disease naïve to anti-TNF: a multicenter study.
Gastroenterology, 142 (2012), pp. S348
[27.]
A. Armuzzi, M. Marzo, C. Felice, D. Pugliese, G. Andrisani, A. Parello, et al.
Complex perianal Crohn's disease: effectiveness of combined seton placement and anti-TNF alpha agents in monotherapy or in association with immunosuppressants.
Gastroenterology, 142 (2012), pp. S354
[28.]
K. Keyashian, B.L. Surma, J.T. Williams, R.D. Cohen, I.H. Hanan, L.H. Raffals, et al.
Interobserver and intraobserver agreement of the mayo score of endoscopic activity in ulcerative colitis.
Gastroenterology, 142 (2012), pp. S660
[29.]
L.N. Rosenberg, G. Lawlor, A.E. Gifford, K.R. Falchuk, J.L. Wolf, A.S. Cheifetz, et al.
Predictors of deep remission in patients with inactive ulcerative colitis.
Gastroenterology, 142 (2012), pp. S660-S661
[30.]
N. De Suray, J. Salleron, G. Vernier-Massouille, J.C. Grimaud, Y. Bouhnik, D. Laharie, et al.
Close monitoring of CRP and fecal calprotectin is able to predict clinical relapse in patients with Crohn's disease in remission after infliximab withdrawal. A subanalysis of the Stori Study.
Gastroenterology, 142 (2012), pp. S149
[31.]
T. Molnár, K. Farkas, F. Nagy, P.L. Lakatos, Z. Szepes, M. Pal, et al.
High restarting rate among patients with Crohn's disease after cessation of one-Year treatment period with biologicals: result of National Rash Study.
Gastroenterology, 142 (2012), pp. S352-S353
[32.]
N. Kennedy, J. Van Ross, N. Hare, G. Ho, H. Drummond, A. Shand, et al.
Acute severe ulcerative colitis: the last twelve years in Edinburgh.
Gastroenterology, (2012), pp. 142
[33.]
A. Sambuelli, A.H. Gil, S.M. Negreira, S.P. Huernos, S.A. Goncalves, P.R. Tirado, et al.
Predictive factors for colectomy in severe corticosteroid (CS) refractory ulcerative colitis (UC) treated with infliximab (IFX).
Gastroenterology, 142 (2012), pp. S362
[34.]
A. Oussalah, I. Aimone-Gastin, S. Salignac, M.A. Bigard, J.L. Gueant, L. Peyrin Biroulet.
Predictors of clinical remission in ulcerative colitis patients treated with anti-TNF: results from a prospective study.
Gastroenterology, 142 (2012), pp. S656-S657
[35.]
J.P. Gisbert, J. Panes.
Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.
Am J Gastroenterol, 104 (2009), pp. 760-767
[36.]
M. Chaparro, I. Guerra, P. Muñoz-Linares, J.P. Gisbert.
Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease.
Aliment Pharmacol Ther, (2012),
[37.]
I. Guerra, M. Chaparro, F. Bermejo, J.P. Gisbert.
Utility of measuring serum concentrations of anti-TNF agents and anti-drug antibodies in inflammatory bowel disease.
Curr Drug Metab, 12 (2011), pp. 594-598
[38.]
W. Reinisch, B.G. Feagan, P.J. Rutgeerts, O.J. Adedokun, F.J. Cornillie, R. Diamond, et al.
Infliximab concentration and clinical outcome in patients with ulcerative colitis.
Gastroenterology, 142 (2012), pp. S114
[39.]
S. Murthy, K. Kevans, C. Seow, A. Newman, A. Steinhart, M. Silverberg, et al.
Association of serum infliximab and antibodies to infliximab to long-term clinical outcome in acute ulcerative colitis.
Gastroenterology, (2012), pp. 142
[40.]
D. Kevans, S. Murthy, A. Iacono, M.S. Silverberg, G.R. Greenberg.
Accelerated clearance of serum infliximab during induction therapy for acute ulcerative colitis is associated with treatment failure.
Gastroenterology, (2012), pp. 142
[41.]
T. Hibi, A. Sakuraba, M. Watanabe, S. Motoya, H. Ito, N. Sato, et al.
Decrease in serum infliximab level precedes loss of clinical response and can be easily detected by the elevation of Creactive protein in Crohn's disease.
Gastroenterology, 142 (2012), pp. S388
[42.]
H. Yanai, L. Mlynarsky, Y. Ron, M. Ben Yehoyada, D. Yeshuron, E.M. Santo, et al.
The questionable value of infliximab trough levels during prolonged maintenance therapy.
Gastroenterology, 142 (2012), pp. S788-S789
[43.]
A. Lalvani, M. Pareek.
Interferon gamma release assays: principles and practice.
Enferm Infecc Microbiol Clin, 28 (2010), pp. 245-252
[44.]
F. Bermejo, A. Algaba, A. Chaparro, C. Taxonera, A. López-Sanroman, I. Guerra.
How frequent are conversions of tuberculosis (TBC) screening tests among inflammatory bowel disease (IBD) patients under anti-TNF treatment?.
Gastroenterology, 142 (2012), pp. S667
[45.]
P. Papay, C. Primas, A. Eser, G. Novacek, F. Winkler, S. Frantal, et al.
Retesting for latent tuberculosis in patients with inflammatory bowel disease after exposure to biologics.
Gastroenterology, 142 (2012), pp. S669
[46.]
C. Stone, J. Chen, E. Armbrecht.
Utility of annual testing for tuberculosis infection during treatment with anti-tumor necrosis factor alpha medications.
Gastroenterology, 142 (2012), pp. S206
[47.]
J.P. Gisbert.
Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding.
Inflamm Bowel Dis, 16 (2010), pp. 881-895
[48.]
M. Ujihara, T. Ando, K. Ishiguro, O. Maeda, O. Watanabe, S. Hibi, et al.
Appropriate pharmaceutical management is crucial for pregnant women complicated by ulcerative colitis.
Gastroenterology, 142 (2012), pp. S251-S252
[49.]
M.J. Casanova, M. Chaparro, E. Domenech, M. Barreiro-de Acosta, F. Bermejo, E. Iglesias Flores, et al.
Safety of immunomodulators and anti-TNF drugs for the treatment of inflammatory bowel disease (IBD) during pregnancy.
Gastroenterology, 142 (2012), pp. S362-S363
[50.]
R. Marchioni, W. Blonski, G. Lichtenstein.
TNF-alpha inhibitor therapy and fetal risk: a systematic literature review.
Gastroenterology, 142 (2012), pp. S248-S249
[51.]
M. Chaparro, J.P. Gisbert.
Transplacental transfer of immunosuppressants and biologics used for the treatment of inflammatory bowel disease.
Curr Pharm Biotechnol, 12 (2011), pp. 765-773
[52.]
U. Mahadevan, C. Martin, R. Sandler, S. Kane, M. Dubinsky, J. Lewis, et al.
PIANO: A 1,000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy.
Gastroenterology, 142 (2012), pp. S149
[53.]
Z. Zelinkova, C. Van der Ent, K. Bruin, O. Van Baalen, H. Vermeulen, H. Smalbraak, et al.
Early discontinuation of infliximab during pregnancy reduces neonatal exposure to infliximab and is safe for the inflammatory bowel disease patients.
Gastroenterology, (2012), pp. 142
[54.]
Z. Zelinkova, C. Van der Ent, E. Kuipers, C.J. Van der Woude.
Prospective assessment of the adalimumab discontinuation during pregnancy in inflammatory bowel disease patients.
Gastroenterology, 142 (2012), pp. S385-S386
Copyright © 2012. Elsevier España, S.L.. Todos los derechos reservados
